New York City, NY -- (SBWIRE) -- 05/02/2019 -- AMD is a disease in which blurred vision or blindness occurs due to damage to the retina macula. Wet AMD is a type of AMD characterized by the growth of abnormal blood vessels under the retina and macula.

On the basis of product, the wet age-related macular degeneration market is categorized into Eylea, Avastin, Lucentis, and others. Out of these, during the historical period (2014–2018), the Eylea category witnessed the fastest growth, and it is expected to keep growing during the forecast period at a CAGR of 10.0%. This is mainly attributed to the surging demand for this medication due to its low cost as well as high efficiency in the management of exudative or wet AMD.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market/report-sample

The wet age-related macular degeneration market is divided into direct and indirect channels on the basis of distribution channel. Of these, in 2018, the direct channel category held more than 60.0% share in the market, owing to the fact that a direct channel of distribution demands less investment and excludes the need for a third person for the supply of products, thereby making the process simpler and shorter. Hence, market players prefer selling their products directly to pharmacies and medical stores.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=wet-age-related-macular-degeneration-market

The risk of developing AMD is directly proportional to age. With the number of people aged 60 years and above rising, the prevalence of AMD is also increasing. According to the World Population Prospects data published by the United Nations (UN), in 2017, there were about 962 million people in the age group 60 years or over across the globe, and the number is predicted to more than double by 2050, reaching 2.1 billion ultimately. Thus, it can be concluded that the geriatric population is rising faster than younger age groups.

Japan, Germany, Italy, and Portugal are among the nations with the largest population of elderly in the world. As older people are more prone to degenerative disorders, the increasing geriatric population in these countries is anticipated to contribute to the rising demand for drugs for wet AMD treatment, thus driving the wet age-related macular degeneration market during the forecast period.

Therefore, the surging geriatric population across the world is pushing the demand for drugs for treating wet AMD, resulting in the growth of the market.